Clinical Trial Update: A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating SHR-A1811 in combination with Fluzoparib for HER2-expressing cancers (advanced solid tumors).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Fluzoparib (fluzoparib)
• SHR-A1811

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: Advanced Solid Tumors | Phase 2 | Status: UNKNOWN